CIK 0001671858
- Non-accelerated filer
- Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811489190
- Phone
- +1 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-08 | Thompson Peter A. Director | Conversion · Series A Preferred Stock | −12,857,142 | 0 | ||
| 2020-12-08 | Thompson Peter A. Director | Conversion · Series B Preferred Stock | −9,259,259 | 0 | ||
| 2020-12-08 | Thompson Peter A. Director | Conversion · Series C Preferred Stock | −3,918,279 | 0 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Purchase | +238,100 | $21.00 | $5.0M | 507,423 |
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +3,462,737 | 3,970,160 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +2,493,741 | 6,463,901 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +1,055,287 | 7,519,188 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Purchase | +952,377 | $21.00 | $20.0M | 952,377 |
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −12,857,142 | 0 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −9,259,259 | 0 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −3,918,279 | 0 | ||
| 2020-12-03 | Thompson Peter A. Director | Grant or award · Stock Option (right to buy) | +38,270 | 38,270 | ||
| 2020-12-03 | Odegard Valerie President and CSO | Grant or award · Stock Option (right to buy) | +364,904 | 364,904 | ||
| 2020-12-03 | Shawver Laura Chief Executive Officer | Grant or award · Stock Option (right to buy) | +562,631 | 562,631 | ||
| 2020-12-03 | ROOT JONATHAN D Director | Grant or award · Stock Option (right to buy) | +38,270 | 38,270 | ||
| 2020-12-03 | Powell Andrew Kenneth William Director | Grant or award · Stock Option (right to buy) | +21,009 | 21,009 | ||
| 2020-12-03 | Piazza Jonathan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +74,730 | 74,730 | ||
| 2020-12-03 | Islam Saqib Director | Grant or award · Stock Option (right to buy) | +69,753 | 69,753 | ||
| 2020-12-03 | Hunder Naomi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +231,071 | 231,071 | ||
| 2020-12-03 | HERSHBERG ROBERT Director | Grant or award · Stock Option (right to buy) | +73,251 | 73,251 |
Page 30 of 31 · 602 trades